Alfuzosin

psilodex.org/m/alfuzosin · data v2026.10.02

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Mechanism only; Also: standard practice.
Half-life: ~10 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: alfuzosin · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Th · Pr

Postural hypotension, with or without dizziness, can develop within a few hours of a dose and adds to lightheadedness on standing during a session. The label urges caution with QT prolongation or other QT-prolonging medicines.

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: ~10 h (apparent elimination half-life, 10 mg extended-release) (FDA label, checked 2026-10-02)

Evidence types on this record

ThMechanism only (theoretical)

PrStandard practice; no psilocybin-specific data

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

Lowers blood pressure or causes orthostasis: Lowers blood pressure, or causes a drop on standing (orthostasis) that can bring dizziness or fainting. Sources [1]
QT-prolonging: Lengthens the QT interval on an ECG, a measure of the heart’s electrical recovery between beats. A long QT raises the risk of a dangerous heart rhythm, more so with other QT-prolonging drugs or low potassium or magnesium. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Uroxatral (Alfuzosin HCl) Tablet, Extended Release · FDA label (DailyMed) — 5.1 postural hypotension; 5.9 congenital or acquired QT prolongation

Record history

v2026.10.02First published.
2026-10-02Last reviewed against its sources.

Report an error in this record →